Lenalidomide-based response-adapted therapy for older adults without high risk myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baz, Rachid | - |
dc.contributor.author | Mahrukh, Syeda | - |
dc.contributor.author | Naqvi, Hussnain | - |
dc.contributor.author | Lee, Jae-Hoon | - |
dc.contributor.author | Brayer, Jason | - |
dc.contributor.author | Hillgruber, Nancy | - |
dc.contributor.author | Fridley, Brooke L. | - |
dc.contributor.author | Shain, Kenneth H. | - |
dc.contributor.author | Sullivan, Daniel M. | - |
dc.contributor.author | Alsina, Melissa | - |
dc.date.available | 2020-02-27T04:40:51Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 0007-1048 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1762 | - |
dc.description.abstract | Combined lenalidomide and dexamethasone is a standard-of-care therapy for the treatment of older adults with multiple myeloma. Lenalidomide monotherapy has not been evaluated in newly diagnosed myeloma patients. We conducted a phase II study, evaluating a response-adapted therapy for older adults newly diagnosed with multiple myeloma without high-risk features who were ineligible for high-dose therapy and stem cell transplant. Patients were started on single-agent lenalidomide, and low-dose dexamethasone was added in the event of progressive disease, in a response-adapted approach. The primary endpoint was progression-free survival (PFS), and the International Myeloma Working Group's uniform response criteria were used to assess response and progression. Twenty-seven patients were enrolled, and 20 (74%) experienced a partial response or better to this response-adapted therapy. After a median follow-up of 69 months, the median PFS was 36 months [95% confidence interval (CI), 29 center dot 8 to not reached], and the median overall survival was 65 months (95% CI, 35 center dot 3 to not reached). Grade 3/4 adverse events were mainly haematological in nature. This response-adapted therapy in this patient population is feasible and results in durable responses that compare favourably with concurrent lenalidomide and dexamethasone. These results should be validated in prospective studies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.subject | PREDNISONE PLUS THALIDOMIDE | - |
dc.subject | DIAGNOSED MULTIPLE-MYELOMA | - |
dc.subject | SINGLE-AGENT LENALIDOMIDE | - |
dc.subject | LONG-TERM SURVIVAL | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | BORTEZOMIB | - |
dc.subject | MELPHALAN | - |
dc.subject | EFFICACY | - |
dc.title | Lenalidomide-based response-adapted therapy for older adults without high risk myeloma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000458970900006 | - |
dc.identifier.doi | 10.1111/bjh.15700 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF HAEMATOLOGY, v.184, no.5, pp.735 - 743 | - |
dc.identifier.scopusid | 2-s2.0-85058224628 | - |
dc.citation.endPage | 743 | - |
dc.citation.startPage | 735 | - |
dc.citation.title | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.citation.volume | 184 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Lee, Jae-Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | myeloma | - |
dc.subject.keywordAuthor | lenalidomide | - |
dc.subject.keywordAuthor | older adults | - |
dc.subject.keywordAuthor | response-adapted therapy | - |
dc.subject.keywordPlus | PREDNISONE PLUS THALIDOMIDE | - |
dc.subject.keywordPlus | DIAGNOSED MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | SINGLE-AGENT LENALIDOMIDE | - |
dc.subject.keywordPlus | LONG-TERM SURVIVAL | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | BORTEZOMIB | - |
dc.subject.keywordPlus | MELPHALAN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.